Cantor Fitzgerald began coverage on shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in a research note published on Tuesday, October 24th, MarketBeat.com reports. The firm issued an overweight rating and a $22.00 price target on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Aldeyra Therapeutics’ FY2017 earnings at ($1.30) EPS and FY2018 earnings at ($1.29) EPS.
Several other brokerages also recently issued reports on ALDX. ValuEngine downgraded shares of Aldeyra Therapeutics from a sell rating to a strong sell rating in a research report on Wednesday, September 6th. Cowen and Company reiterated an outperform rating and issued a $14.00 price target (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Canaccord Genuity reiterated a buy rating and issued a $27.00 price target (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a hold rating to a sell rating in a research report on Tuesday, October 10th. Finally, HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the company a buy rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $16.96.
Aldeyra Therapeutics (NASDAQ ALDX) opened at $5.95 on Tuesday. Aldeyra Therapeutics has a 1-year low of $3.80 and a 1-year high of $11.90. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.04.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. equities analysts predict that Aldeyra Therapeutics will post -1.39 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Aldeyra Therapeutics, Inc. (ALDX) Now Covered by Cantor Fitzgerald” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/12/aldeyra-therapeutics-inc-aldx-research-coverage-started-at-cantor-fitzgerald.html.
In related news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were purchased at an average price of $7.25 per share, with a total value of $1,450,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 28.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. Sphera Funds Management LTD. grew its stake in shares of Aldeyra Therapeutics by 19.2% in the third quarter. Sphera Funds Management LTD. now owns 1,044,131 shares of the biotechnology company’s stock worth $7,518,000 after purchasing an additional 168,200 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Aldeyra Therapeutics in the third quarter worth $134,000. Virtu KCG Holdings LLC bought a new stake in shares of Aldeyra Therapeutics in the second quarter worth $104,000. Vanguard Group Inc. grew its stake in shares of Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares during the last quarter. Finally, Hikari Power Ltd grew its stake in shares of Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 70,196 shares during the last quarter. 40.25% of the stock is currently owned by institutional investors.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.